Together this suggests that PD-1 and PD-L1 may not play as large a role to the immunosuppressive landscape of glioblastoma compared to other cancer types and that potentially targeting other immunoregulatory receptors in the glioblastoma setting may be more beneficial. The gene discussed is PDCD1; the disease is cancer.